Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.79 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.79 |
| ▸ | IDO1 | P14902 | 5/20 | 0.79 |
| ▸ | HPGDS | O60760 | 1/20 | 0.62 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1501929 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3823466 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL1949527 | 0.86 | CYP11B1 (1.00) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL1948768 | 0.84 | CYP11B1 (0.79) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL1951962 | 0.84 | CYP11B1 (0.79) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3968212 | 0.84 | CYP11B1 (0.79) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3822956 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3969042 | 0.82 | CYP11B1 (0.74) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3972715 | 0.81 | CYP11B1 (0.79) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3969041 | 0.81 | CYP11B1 (0.75) | CYP11B1CYP11B2IDO1HPGDSP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | CYP11B1 525/4885CYP11B2 982/4885IDO1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.